Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 8/20 | 0.50 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14367609 | 0.80 | RAB9A (0.71) | NPY2RRAB9ATDP1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22875089 | 0.76 | ALDH1A1 (0.43) | TDP1ALDH1A1 | |
| SCHEMBL9911362 | 0.74 | RAB9A (0.60) | RAB9ASMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL8117431 | 0.72 | RAB9A (0.61) | RAB9ASMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL6706826 | 0.71 | SMN1; SMN2 (0.56) | RAB9ASMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL6706829 | 0.71 | SMN1; SMN2 (0.56) | RAB9ASMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL28818049 | 0.70 | CA1 (0.61) | RAB9ASMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL10666828 | 0.69 | HPGD (0.56) | RAB9ASMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL1542810 | 0.69 | RAB9A (0.64) | RAB9ASMN1; SMN2ALDH1A1GAANPC1 | |
| SCHEMBL10398453 | 0.69 | MAPT (0.61) | RAB9ASMN1; SMN2ALDH1A1GAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | NPY2R 1119/4885RAB9A 1585/4885FDFT1 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.